Skip to main content

Table 4 Results of currently approved CAR-T cell products for B-cell lymphoma

From: Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities

Cell product Target Cell dose Indication Clinical significance Complications References
Tisagenlecleucel (Kymriah) CD19 0.1–6 × 108 R/R DLBCL ORR 52%, CR 40%, PR 12% Cytopenias:32%
Infections:20%
NEs (grade 3 or worse):12%, CRS (grade 3 or worse):22%
[122]
Axicabtagene ciloleucel (Yescarta) CD19 2 × 106/kg R/R large B-cell lymphoma ORR 83%, CR 58% Pyrexia:87%
Anaemia:68%
NEs (grade 3 or worse):32%
CRS (grade 3 or worse):11%
[123]
   2 × 106/kg R/R FL ORR 95%, CR 80% NEs (grade 3 or worse):19%
CRS (grade 3 or worse):11%
[124]
Brexucabtagene Autoleucel (Tecartus) CD19 2 × 106/kg R/R MCL ORR 85%, CR 58% Cytopenias:94%
Infections:32%
NEs (grade 3 or worse):31%, CRS (grade 3 or worse):15%
[125]
Lisocabtagene maraleucel (Breyanzi) CD19 50/100/150 × 106 R/R large B-cell lymphoma ORR 73%, CR 53% Neutropenia:60%
Anaemia:37%
Thrombocytopenia:27%
NEs (grade 3 or worse):10%, CRS (grade 3 or worse):2%
[126]